NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00362232,Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.,https://clinicaltrials.gov/study/NCT00362232,RECORD 4,COMPLETED,"The purpose of this study is to assess if 10 mg BAY59-7939, taken once daily as a tablet, is safe and prevents blood clot which may form after a knee replacement operation.",YES,Venous Thromboembolism,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Enoxaparin|DRUG: Placebo: tablet of Rivaroxaban|DRUG: Placebo: syringes of Enoxaparin","Composite Endpoint of Total Venous Thrombo Embolism (VTE) i.e.: Any Deep Vein Thromboembolism (DVT) (Proximal and/or Distal), Non Fatal Pulmonary Embolism (PE), Death of All Causes Per Protocol Population, Blinded, adjudicated assessment of bilateral venography, clinical signs of deep vein thrombosis (DVT) and pulmonary embolism (PE), ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography, Up to 16 days after surgery|Composite Endpoint of Total VTE i.e.: Any DVT (Proximal and/or Distal), Non Fatal PE, Death of All Causes Per Modified Intent to Treat Population., Blinded, adjudicated assessment of bilateral venography, clinical signs of deep vein thrombosis (DVT) and pulmonary embolism (PE), ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography, Up to 16 days after surgery","Incidence of the Composite Endpoint Comprising Proximal DVT, Non-fatal PE and VTE- Related Death (Major VTE) Per Protocol Population of Major VTE, Blinded, adjudicated assessment of bilateral venography, clinical signs of deep vein thrombosis (DVT) and pulmonary embolism (PE), ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography, Up to 16 days after surgery|Incidence of the Composite Endpoint Comprising Proximal DVT, Non-fatal PE and VTE- Related Death (Major VTE) Per Modified Intent to Treat Population of Major VTE., Blinded, adjudicated assessment of bilateral venography, clinical signs of deep vein thrombosis (DVT) and pulmonary embolism (PE), ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography, Up to 16 days after surgery|Incidence of Symptomatic VTE (DVT, PE) Per Protocol Population., Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography, Up to 16 days after surgery|Incidence of Symptomatic VTE (DVT, PE) Per Modified Intent to Treat Population., Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography, Up to 16 days after surgery|Incidence of DVT (Proximal, Distal) Per Protocol Population., Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography, Up to 16 days after surgery|Incidence of DVT (Proximal, Distal) Per Modified Intent to Treat Population., Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography, Up to 16 days after surgery|Incidence of Symptomatic VTE During Follow-up Per Protocol Population., Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography, Up to 47 days after surgery|Incidence of Symptomatic VTE During Follow-up Per Modified Intent to Treat Population., Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography, Up to 47 days after surgery|The Composite Endpoint Comprising Major VTE and Treatment-emergent Major Bleeding Per Subjects Valid for Analysis of Net Clinical Benefit, Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography, anesthesia and surgery reports, number of transfusions, Up to 47 days after surgery|Incidence of the Composite Endpoint That Results From the Primary Endpoint by Substituting VTE Related Death for All Death Per Protocol Population., Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography, Up to 16 days after surgery|Incidence of the Composite Endpoint That Results From the Primary Endpoint by Substituting VTE Related Death for All Death Per Modified Intent to Treat Population., Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography, Up to 16 days after surgery|Incidence of the Composite Endpoint That Results From Major VTE by Substituting All Cause Mortality for VTE-related Death Per Protocol of Major VTE Population., Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography, Up to 16 days after surgery|Incidence of the Composite Endpoint That Results From Major VTE by Substituting All Cause Mortality for VTE-related Death Per Modified Intent to Treat of Major VTE Population., Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography, Up to 16 days after surgery|Treatment-emergent Major Bleedings Per Safety Population., Blinded, adjudicated assessments of all available information (eg, anesthesia and surgery reports, laboratory results, number of transfusions, autopsy report), from start of double-blind study medication to last dose of double-blind study medication plus two days. The average duration of double-blind treatment was 12 days in each treatment group (safety population).",,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,3148,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",11355|2006-002402-60,2006-06,2007-01,2008-01,2006-08-09,2012-06-13,2014-11-04,"Birmingham, Alabama, 35209, United States|Tuscaloosa, Alabama, 35406, United States|Phoenix, Arizona, 85023, United States|Little Rock, Arkansas, 72205, United States|Bakersfield, California, 93309, United States|Encinitas, California, 92024, United States|Fountain Valley, California, 92708, United States|La Jolla, California, 92037, United States|Torrance, California, 90502-2004, United States|Yuba City, California, 95991, United States|Centennial, Colorado, 80112, United States|Denver, Colorado, 80230, United States|Englewood, Colorado, 80110, United States|Boynton Beach, Florida, 33472-2952, United States|Clearwater, Florida, 33756, United States|DeLand, Florida, 32720, United States|Hollywood, Florida, 33021, United States|Jacksonville, Florida, 32216, United States|Pensacola, Florida, 32501, United States|Pinellas Park, Florida, 33781, United States|Decatur, Georgia, 30033, United States|Boise, Idaho, 83702, United States|Meridian, Idaho, 83642, United States|Towson, Maryland, 21204, United States|Missoula, Montana, 59802, United States|Teaneck, New Jersey, 07666, United States|Greensboro, North Carolina, 27401, United States|Cincinnati, Ohio, 45242, United States|Oklahoma City, Oklahoma, 73162, United States|Johnstown, Pennsylvania, 15901, United States|State College, Pennsylvania, 16801, United States|Charleston, South Carolina, 29414, United States|Dallas, Texas, 75231, United States|Grapevine, Texas, 76051, United States|Houston, Texas, 77030, United States|Lubbock, Texas, 79410, United States|Plano, Texas, 75093, United States|San Antonio, Texas, 78205, United States|San Antonio, Texas, 78233, United States|Spokane, Washington, 99218, United States|Pleven, 5800, Bulgaria|Plovdiv, 4002, Bulgaria|Sofia, 1431, Bulgaria|Red Deer, Alberta, T4N 6V7, Canada|Kelowna, British Columbia, V1W 4V5, Canada|Penticton, British Columbia, V2A 5C8, Canada|Fredericton, New Brunswick, E3B 5N5, Canada|Ajax, Ontario, L1S 2J4, Canada|Brantford, Ontario, N3R 1G9, Canada|Oakville, Ontario, L6J 3M5, Canada|Oshawa, Ontario, L1G 2B9, Canada|Ottawa, Ontario, K1Y 4E9, Canada|Peterborough, Ontario, K9J 7C6, Canada|Scarborough, Ontario, M1M 3W3, Canada|Scarborough, Ontario, M1P 2V5, Canada|Sudbury, Ontario, P3A 1Y8, Canada|Thunder Bay, Ontario, P7B 6V4, Canada|Woodstock, Ontario, N4S 5B2, Canada|Charlottetown, Prince Edward Island, C1A 8T5, Canada|Montreal, Quebec, H3G 1A4, Canada|Montreal, Quebec, H3T 1E2, Canada|Hellerup, DK-2900, Denmark|Herlev, 2730, Denmark|Hvidovre, 2650, Denmark|Hørsholm, 2970, Denmark|Silkeborg, 8600, Denmark|Viborg, 8800, Denmark|Hyderabad, Andhra Pradesh, 500004, India|Secunderabad, Andhra Pradesh, 500 003, India|Secundrabad, Andhra Pradesh, 500003, India|Ahmedabad, Gujarat, 380006, India|Ahmedabad, Gujarat, 380054, India|Pune, Maharashtra, 411001, India|Pune, Maharashtra, 411009, India|Ludhiana, Punjab, 141001, India|Chennai, Tamil Nadu, 600 006, India|Bangalore, 560001, India|Bangalore, 560034, India|Baroda, 390007, India|Hyderabad, India|New Delhi, 110029, India|Beer Sheva, 85025, Israel|Holon, 58100, Israel|Kfar Saba, 44281, Israel|Petach Tikva, 49100, Israel|Tel Aviv, 64239, Israel|Zerifin, 70300, Israel|Kaunas, 44320, Lithuania|Kaunas, LT-50009, Lithuania|Klaipeda, 92288, Lithuania|Panevezys, 35144, Lithuania|Vilnius, LT-04130, Lithuania|Guadalajara, Jalisco, 44200, Mexico|Guadalajara, Jalisco, 44350, Mexico|Zapopan, Jalisco, 45100, Mexico|Monterrey, Nuevo Leon, 64000, Mexico|Monterrey, Nuevo Leon, 64380, Mexico|Mérida, Yucatán, 97150, Mexico|Edo. de Mexico, 53120, Mexico|Baerum postterminal, 1306, Norway|Gjövik, 2819, Norway|Kongsvinger, 2212, Norway|Lillehammer, 2609, Norway|Karachi, Sindh, 74800, Pakistan|Karachi, Sindh, Pakistan|Bydgoszcz, 85-094, Poland|Elblag, 82-300, Poland|Gdansk, 80-803, Poland|Kielce, Poland|Konskie, 26-200, Poland|Krakow, 31-913, Poland|Lublin, 20-718, Poland|Sosnowiec, 41-200, Poland|Warszawa, 02-005, Poland|Warszawa, 02-507, Poland|Colombo-80, Sri Lanka|Kotte, Sri Lanka|Ragama, Sri Lanka|Göteborg, 416 85, Sweden|Hässleholm, 281 25, Sweden|Stockholm, 112 81, Sweden|Västervik, 593 81, Sweden|Växjö, 351 85, Sweden|Örebro, 701 85, Sweden",
